Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 ...

This year, pharmaceutical giant Merck (NYSE: MRK ... such as its pair of HPV vaccines, Gardasil and Gardasil 9. Further, the company has a deep pipeline, with more than 80 programs in phase ...

Merck will face an important patent cliff by ... such as its pair of HPV vaccines, Gardasil and Gardasil 9. Further, the company has a deep pipeline, with more than 80 programs in phase 2 studies ...

A US Centers for Disease Control and Prevention’s (CDC) Advisory Committee (AdCom) on Immunization Practice (ACIP) voted in ...

Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...

Meanwhile, Merck is also working on two follow-up conjugate vaccines – V116 and V117 – that will extend its range. V116 is a specifically targeting adult disease, and the most common serotypes ...

Merck's Vaxneuvance – formerly known as V114 – is the first major competition to Pfizer's franchise in the big market for conjugate pneumococcal vaccines ... with its off-label use.

The recommendation, backed by CDC director Mandy Cohen, affects approved pneumococcal vaccines such as MSD (Merck & Co)’s Capvaxive ... the agency expanded the vaccine label to include infants ...